Literature DB >> 7361854

Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants.

J F Van Vleet, V J Ferrans, W E Weirich.   

Abstract

Chronic adriamycin (ADR) intoxication was produced in three groups of beagle dogs by weekly intravenous injections (1 mg/kg body weight) for 20 weeks (cumulative dose 400 mg/sq m). Group A (6 dogs) received ADR only; Group B (6 dogs) were given ADR and weekly doses of vitamin E (17 mg/kg body weight) as alpha-tocopherol acetate; and Group C (6 dogs) received ADR and weekly doses of vitamin E as did Group B and selenium (0.06 mg/kg body weight as selenite). Each of the 18 dogs developed ADR-induced cardiomyopathy (CMY), and death occurred in 11 dogs during Weeks 17-20. Mortality was lowest in Group B (2 of 6), but no differences between groups were seen either in survival time of the dogs that died or in severity of CMY. Cardiomyopathy was more severe in dogs that died than in survivors. Congestive heart failure with transudation was present in 4 of 11 dogs that died. Cardiac histopathology was characterized by vacuolar degeneration of myocytes. Myocardial damage was most severe in the left ventricle and the ventricular septum, intermediate in the right ventricle and the left atrium, and least in the right atrium. Ultrastructural study showed that an early alteration in damaged myocytes was distention of sarcoplasmic reticulum to form sarcoplasmic vacuoles. Occasional damaged fibers had myofibrillar lysis and focal proliferation of sarcoplasmic reticulum. This study demonstrates that the dog offers a suitable model for studies of chronic ADR cardiotoxicity in man. The lack of cardioprotection from vitamin E and selenium supplementation fails to support the proposed role of lipoperoxidative damage in the development of chronic ADR-induced CMY.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7361854      PMCID: PMC1903483     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

Review 1.  Myofibrillar abnormalities following cardiac muscle cell injury.

Authors:  V J Ferrans; L M Buja; B J Maron
Journal:  Recent Adv Stud Cardiac Struct Metab       Date:  1975

2.  Myocardial ultrastructure in patients with chronic aortic valve disease.

Authors:  B J Maron; V J Ferrans; W C Roberts
Journal:  Am J Cardiol       Date:  1975-05       Impact factor: 2.778

3.  A clinicopathologic analysis of adriamycin cardiotoxicity.

Authors:  E A Lefrak; J Pitha; S Rosenheim; J A Gottlieb
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

4.  Cardiac ultrastructural changes induced by daunorubicin therapy.

Authors:  L M Buja; V J Ferrans; R J Mayer; W C Roberts; E S Henderson
Journal:  Cancer       Date:  1973-10       Impact factor: 6.860

5.  An anthracycline antibiotic-induced cardiomyopathy in rabbits.

Authors:  R S Jaenke
Journal:  Lab Invest       Date:  1974-03       Impact factor: 5.662

6.  Chronic toxicity of adriamycin: a new antineoplastic antibiotic.

Authors:  C Bertazzoli; T Chieli; G Ferni; G Ricevuti; E Solcia
Journal:  Toxicol Appl Pharmacol       Date:  1972-03       Impact factor: 4.219

Review 7.  Biochemical function of selenium and its relation to vitamin E.

Authors:  W G Hoekstra
Journal:  Fed Proc       Date:  1975-10

8.  The spectrum of degenerative changes in hypertrophied human cardiac muscle cells: an ultrastructural study.

Authors:  B J Maron; V J Ferrans; M Jones
Journal:  Recent Adv Stud Cardiac Struct Metab       Date:  1975

9.  Combined cardiotoxicity of adriamycin and x-radiation.

Authors:  L F Fajardo; J R Eltringham; J R Steward
Journal:  Lab Invest       Date:  1976-01       Impact factor: 5.662

10.  Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits.

Authors:  H M Olson; D M Young; D J Prieur; A F LeRoy; R L Reagan
Journal:  Am J Pathol       Date:  1974-12       Impact factor: 4.307

View more
  19 in total

1.  Covalent protein binding of reactive adriamycin metabolites in rat liver and rat heart microsomes.

Authors:  M E Scheulen; H Kappus; A Nienhaus; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

2.  Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.

Authors:  Salim Khiati; Ilaria Dalla Rosa; Carole Sourbier; Xuefei Ma; V Ashutosh Rao; Leonard M Neckers; Hongliang Zhang; Yves Pommier
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

3.  Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo.

Authors:  Sankarganesh Arunachalam; Sun Young Kim; Sun Hwa Lee; Young Hee Lee; Min Sun Kim; Bong Sik Yun; Ho Keun Yi; Pyoung Han Hwang
Journal:  J Nat Med       Date:  2011-08-21       Impact factor: 2.343

Review 4.  Adriamycin-induced heart failure: mechanism and modulation.

Authors:  P K Singal; T Li; D Kumar; I Danelisen; N Iliskovic
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

Review 5.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

6.  Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.

Authors:  Mohamed M Sayed-Ahmed
Journal:  Saudi Pharm J       Date:  2010-08-05       Impact factor: 4.330

7.  Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity.

Authors:  J A Jackson; J P Reeves; K H Muntz; D Kruk; R A Prough; J T Willerson; L M Buja
Journal:  Am J Pathol       Date:  1984-10       Impact factor: 4.307

8.  Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model.

Authors:  D A Dodd; J B Atkinson; R D Olson; S Buck; B J Cusack; S Fleischer; R J Boucek
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

9.  Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits.

Authors:  N V Dimitrov; M B Hay; S Siew; D A Hudler; L J Charamella; D E Ullrey
Journal:  Am J Pathol       Date:  1987-02       Impact factor: 4.307

10.  Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.

Authors:  O Popelová; M Sterba; P Hasková; T Simůnek; M Hroch; I Guncová; P Nachtigal; M Adamcová; V Gersl; Y Mazurová
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.